| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.975 | 0.002 | 0.975 | Histone deacetylase 1 inhibitor | 0.252 0.005 DBMET03681 | ||
| 0.973 | 0.002 | 0.973 | Histone deacetylase 6 inhibitor | 0.493 0.003 DBMET03681 | ||
| 0.972 | 0.002 | 0.972 | Histone deacetylase class IIb inhibitor | 0.492 0.004 DBMET03681 | ||
| 0.965 | 0.002 | 0.965 | Histone deacetylase class II inhibitor | 0.449 0.003 DBMET03681 | ||
| 0.938 | 0.002 | 0.938 | Histone deacetylase 2 inhibitor | 0.257 0.005 DBMET03681 | ||
| 0.803 | 0.002 | 0.803 | Histone deacetylase class IV inhibitor | 0.117 0.005 DBMET03681 | ||
| 0.803 | 0.002 | 0.803 | Histone deacetylase 11 inhibitor | 0.117 0.005 DBMET03681 | ||
| 0.799 | 0.003 | 0.799 | Histone deacetylase 3 inhibitor | 0.13 0.006 DBMET03681 | ||
| 0.795 | 0.002 | 0.795 | Histone deacetylase class IIa inhibitor | 0.189 0.005 DBMET03681 | ||
| 0.793 | 0.002 | 0.793 | Histone deacetylase 5 inhibitor | 0.225 0.005 DBMET03681 | ||
| 0.791 | 0.001 | 0.791 | Aminopeptidase microsomal inhibitor | 0.135 0.01 DBMET03681 | ||
| 0.783 | 0.001 | 0.783 | Aminopeptidase N inhibitor | 0.118 0.01 DBMET03681 | ||
| 0.78 | 0.004 | 0.78 | Tumour necrosis factor alpha release inhibitor | |||
| 0.763 | 0.002 | 0.763 | Histone deacetylase 10 inhibitor | 0.113 0.005 DBMET03681 | ||
| 0.744 | 0.002 | 0.744 | Peroxidase inhibitor | 0.481 0.011 DBMET00137 0.527 0.008 DBMET03681 | ||
| 0.728 | 0.003 | 0.728 | 5-Lipoxygenase inhibitor | 0.149 0.038 DBMET03681 | ||
| 0.717 | 0.002 | 0.717 | Leukotriene A4 hydrolase inhibitor | |||
| 0.715 | 0.005 | 0.715 | Platelet antagonist | 0.333 0.043 DBMET03681 | ||
| 0.56 | 0.002 | 0.56 | Chemokine receptor agonist | |||
| 0.543 | 0.014 | 0.543 | Lipoxygenase inhibitor | |||
| 0.529 | 0.002 | 0.529 | Glutamate decarboxylase inhibitor | 0.178 0.009 DBMET00137 0.289 0.004 DBMET03681 | ||
| 0.512 | 0.002 | 0.512 | CXC chemokine receptor agonist | |||
| 0.501 | 0.003 | 0.501 | Histone deacetylase 4 inhibitor | 0.104 0.005 DBMET03681 | ||
| 0.494 | 0.003 | 0.494 | Leukotriene synthesis inhibitor | |||
| 0.435 | 0.001 | 0.435 | Retinoic acid alpha receptor agonist | |||
| 0.412 | 0.003 | 0.412 | Macrophage elastase inhibitor | 0.052 0.023 DBMET03681 | ||
| 0.404 | 0.004 | 0.404 | Urease inhibitor | 0.102 0.064 DBMET00137 0.115 0.05 DBMET03681 | ||
| 0.401 | 0.003 | 0.401 | Triose-phosphate isomerase inhibitor | 0.296 0.005 DBMET00137 0.293 0.005 DBMET03681 | ||
| 0.401 | 0.004 | 0.401 | Alcohol oxidase inhibitor | 0.359 0.004 DBMET00137 0.18 0.008 DBMET03681 | ||
| 0.437 | 0.071 | 0.536 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.536 0.02 DBMET00137 0.459 0.056 DBMET03681 | DBMET00137 | |
| 0.382 | 0.025 | 0.382 | Insulysin inhibitor | 0.297 0.06 DBMET00137 0.308 0.054 DBMET03681 | ||
| 0.347 | 0.007 | 0.526 | GABA C receptor agonist | 0.526 0.003 DBMET00137 0.431 0.004 DBMET03681 | DBMET00137 | |
| 0.341 | 0.005 | 0.341 | Adenylate kinase inhibitor | 0.277 0.008 DBMET00137 0.208 0.014 DBMET03681 | ||
| 0.347 | 0.017 | 0.42 | Tyrosine 3 hydroxylase inhibitor | 0.394 0.009 DBMET00137 0.42 0.006 DBMET03681 | DBMET03681 | |
| 0.362 | 0.034 | 0.378 | Superoxide dismutase inhibitor | 0.378 0.031 DBMET00137 0.259 0.069 DBMET03681 | DBMET00137 | |
| 0.329 | 0.004 | 0.329 | GABA C receptor antagonist | 0.257 0.006 DBMET00137 0.274 0.005 DBMET03681 | ||
| 0.307 | 0.002 | 0.307 | ADAM10 endopeptidase inhibitor | 0.112 0.004 DBMET03681 | ||
| 0.308 | 0.008 | 0.308 | Aminopeptidase B inhibitor | 0.181 0.026 DBMET00137 0.193 0.023 DBMET03681 | ||
| 0.371 | 0.075 | 0.614 | GABA C receptor rho-3 antagonist | 0.614 0.006 DBMET00137 0.528 0.019 DBMET03681 | DBMET00137 | |
| 0.379 | 0.087 | 0.379 | Antibacterial | |||
| 0.411 | 0.133 | 0.411 | Antiinflammatory | |||
| 0.278 | 0.002 | 0.278 | Collagenase inhibitor | 0.077 0.008 DBMET03681 | ||
| 0.278 | 0.004 | 0.278 | Phenylalanine 4-hydroxylase inhibitor | 0.156 0.011 DBMET00137 0.181 0.008 DBMET03681 | ||
| 0.292 | 0.02 | 0.292 | Tumour necrosis factor antagonist | |||
| 0.287 | 0.018 | 0.652 | Alpha-N-acetylglucosaminidase inhibitor | 0.652 0.003 DBMET00137 0.525 0.005 DBMET03681 | DBMET00137 | |
| 0.246 | 0.024 | 0.246 | Interleukin 6 antagonist | |||
| 0.235 | 0.016 | 0.398 | Ferrochelatase inhibitor | 0.398 0.004 DBMET00137 0.313 0.006 DBMET03681 | DBMET00137 | |
| 0.271 | 0.057 | 0.275 | Gastrin inhibitor | 0.275 0.053 DBMET00137 0.241 0.091 DBMET03681 | DBMET00137 | |
| 0.211 | 0.002 | 0.211 | Nitric oxide donor | 0.059 0.05 DBMET03681 | ||
| 0.214 | 0.007 | 0.214 | Carbamoyl phosphate synthetase inhibitor | 0.212 0.007 DBMET00137 0.164 0.01 DBMET03681 | ||
| 0.347 | 0.148 | 0.468 | Caspase 9 stimulant | 0.468 0.074 DBMET00137 0.429 0.094 DBMET03681 | DBMET00137 | |
| 0.227 | 0.031 | 0.227 | Phospholipase C inhibitor | 0.193 0.049 DBMET00137 0.188 0.053 DBMET03681 | ||
| 0.263 | 0.069 | 0.427 | 5 Hydroxytryptamine uptake stimulant | 0.427 0.01 DBMET00137 0.341 0.028 DBMET03681 | DBMET00137 | |
| 0.216 | 0.028 | 0.216 | M17 leucyl aminopeptidase inhibitor | |||
| 0.181 | 0.003 | 0.181 | Retinoic acid receptor agonist | |||
| 0.188 | 0.012 | 0.188 | Sphingomyelinase inhibitor | 0.127 0.036 DBMET00137 0.151 0.024 DBMET03681 | ||
| 0.19 | 0.019 | 0.335 | UDP-glucose 4-epimerase inhibitor | 0.335 0.009 DBMET00137 0.319 0.009 DBMET03681 | DBMET00137 | |
| 0.189 | 0.019 | 0.195 | Adenylate cyclase stimulant | 0.195 0.016 DBMET00137 0.183 0.023 DBMET03681 | DBMET00137 | |
| 0.206 | 0.044 | 0.317 | Succinate dehydrogenase inhibitor | 0.317 0.008 DBMET00137 0.258 0.02 DBMET03681 | DBMET00137 | |
| 0.175 | 0.014 | 0.218 | Phosphofructokinase-1 inhibitor | 0.218 0.009 DBMET00137 0.164 0.016 DBMET03681 | DBMET00137 | |
| 0.226 | 0.066 | 0.226 | MAP kinase kinase 2 inhibitor | 0.166 0.107 DBMET00137 | ||
| 0.17 | 0.013 | 0.19 | Glutamate dehydrogenase inhibitor | 0.19 0.011 DBMET00137 0.139 0.018 DBMET03681 | DBMET00137 | |
| 0.189 | 0.035 | 0.189 | Cell wall synthesis inhibitor | 0.165 0.051 DBMET00137 0.161 0.055 DBMET03681 | ||
| 0.233 | 0.08 | 0.287 | DNA synthesis inhibitor | 0.287 0.048 DBMET00137 0.244 0.07 DBMET03681 | DBMET00137 | |
| 0.167 | 0.017 | 0.249 | Histidine decarboxylase inhibitor | 0.189 0.014 DBMET00137 0.249 0.009 DBMET03681 | DBMET03681 | |
| 0.155 | 0.008 | 0.155 | Histone deacetylase inhibitor | 0.061 0.052 DBMET03681 | ||
| 0.155 | 0.01 | 0.155 | Ribonucleoside-diphosphate reductase inhibitor | |||
| 0.15 | 0.007 | 0.15 | Phosphodiesterase 4C inhibitor | |||
| 0.174 | 0.032 | 0.174 | Adenylate cyclase inhibitor | 0.122 0.066 DBMET00137 0.123 0.065 DBMET03681 | ||
| 0.211 | 0.069 | 0.256 | Anesthetic general | 0.256 0.048 DBMET00137 0.172 0.093 DBMET03681 | DBMET00137 | |
| 0.152 | 0.012 | 0.152 | Ribonucleotide reductase inhibitor | |||
| 0.153 | 0.014 | 0.153 | Keratolytic | 0.108 0.026 DBMET00137 0.076 0.054 DBMET03681 | ||
| 0.147 | 0.008 | 0.147 | NMDA receptor agonist | 0.087 0.025 DBMET00137 0.101 0.019 DBMET03681 | ||
| 0.141 | 0.004 | 0.155 | Aconitate hydratase inhibitor | 0.155 0.004 DBMET00137 0.103 0.008 DBMET03681 | DBMET00137 | |
| 0.175 | 0.039 | 0.175 | Monophenol monooxygenase inhibitor | |||
| 0.128 | 0.004 | 0.128 | Glutamate (mGluR4) antagonist | 0.053 0.018 DBMET00137 0.057 0.015 DBMET03681 | ||
| 0.127 | 0.007 | 0.127 | NMDA receptor glycine site agonist | 0.092 0.021 DBMET00137 0.103 0.015 DBMET03681 | ||
| 0.123 | 0.003 | 0.123 | Glucose-6-phosphate isomerase inhibitor | 0.117 0.004 DBMET00137 0.114 0.004 DBMET03681 | ||
| 0.122 | 0.005 | 0.142 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.106 0.01 DBMET00137 0.142 0.004 DBMET03681 | DBMET03681 | |
| 0.177 | 0.061 | 0.18 | ATPase inhibitor | 0.18 0.058 DBMET00137 0.161 0.084 DBMET03681 | DBMET00137 | |
| 0.195 | 0.082 | 0.195 | DNA methylase inhibitor | 0.136 0.131 DBMET00137 | ||
| 0.131 | 0.023 | 0.251 | NADH dehydrogenase inhibitor | 0.251 0.008 DBMET00137 0.186 0.012 DBMET03681 | DBMET00137 | |
| 0.15 | 0.043 | 0.192 | Ca2+-transporting ATPase inhibitor | 0.192 0.004 DBMET00137 0.175 0.009 DBMET03681 | DBMET00137 | |
| 0.12 | 0.014 | 0.208 | Biliverdin reductase inhibitor | 0.208 0.005 DBMET00137 0.146 0.01 DBMET03681 | DBMET00137 | |
| 0.189 | 0.083 | 0.274 | 5 Hydroxytryptamine 3E antagonist | 0.274 0.008 DBMET00137 0.232 0.026 DBMET03681 | DBMET00137 | |
| 0.104 | 0.003 | 0.104 | Peptide deformylase inhibitor | 0.03 0.021 DBMET00137 0.039 0.015 DBMET03681 | ||
| 0.209 | 0.108 | 0.245 | DNA damaging | 0.245 0.083 DBMET03681 | DBMET03681 | |
| 0.2 | 0.1 | 0.299 | RNA-directed DNA polymerase inhibitor | 0.299 0.032 DBMET00137 0.231 0.063 DBMET03681 | DBMET00137 | |
| 0.103 | 0.004 | 0.103 | Immunoglobulin Fc receptor antagonist | 0.069 0.012 DBMET00137 0.075 0.008 DBMET03681 | ||
| 0.132 | 0.033 | 0.273 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.273 0.008 DBMET00137 0.184 0.019 DBMET03681 | DBMET00137 | |
| 0.113 | 0.014 | 0.113 | Antimetabolite | 0.068 0.022 DBMET03681 | ||
| 0.143 | 0.045 | 0.143 | Interleukin 1b antagonist | |||
| 0.127 | 0.031 | 0.167 | Catalase inhibitor | 0.167 0.022 DBMET00137 0.092 0.042 DBMET03681 | DBMET00137 | |
| 0.129 | 0.033 | 0.223 | GABA C receptor rho-1 antagonist | 0.223 0.005 DBMET00137 0.178 0.012 DBMET03681 | DBMET00137 | |
| 0.099 | 0.005 | 0.099 | Glutamate (mGluR group III) antagonist | 0.05 0.021 DBMET00137 0.05 0.021 DBMET03681 | ||
| 0.118 | 0.025 | 0.118 | Metalloproteinase-9 inhibitor | |||
| 0.107 | 0.015 | 0.11 | Ornithine carbamoyltransferase inhibitor | 0.11 0.014 DBMET00137 0.084 0.02 DBMET03681 | DBMET00137 | |
| 0.096 | 0.005 | 0.096 | Aggrecanase 1 inhibitor | 0.055 0.011 DBMET03681 | ||
| 0.111 | 0.019 | 0.111 | Amidase inhibitor | |||
| 0.174 | 0.083 | 0.174 | DNA methyltransferase I inhibitor | 0.139 0.117 DBMET00137 0.133 0.126 DBMET03681 | ||
| 0.134 | 0.045 | 0.205 | 5 Hydroxytryptamine 3A agonist | 0.205 0.014 DBMET00137 0.133 0.046 DBMET03681 | DBMET00137 | |
| 0.121 | 0.035 | 0.174 | Electrolyte absorption antagonist | 0.174 0.012 DBMET00137 0.127 0.031 DBMET03681 | DBMET00137 | |
| 0.191 | 0.105 | 0.294 | Nitric-oxide synthase stimulant | 0.294 0.013 DBMET00137 0.247 0.034 DBMET03681 | DBMET00137 | |
| 0.12 | 0.035 | 0.12 | MAP kinase kinase 1 inhibitor | 0.101 0.055 DBMET00137 | ||
| 0.116 | 0.031 | 0.116 | Metalloproteinase-2 inhibitor | |||
| 0.089 | 0.005 | 0.089 | Adenylate cyclase 1 inhibitor | 0.088 0.005 DBMET00137 0.081 0.008 DBMET03681 | ||
| 0.102 | 0.019 | 0.171 | Argininosuccinate synthase inhibitor | 0.171 0.01 DBMET00137 0.116 0.016 DBMET03681 | DBMET00137 | |
| 0.104 | 0.021 | 0.104 | Neutrophil collagenase inhibitor | |||
| 0.091 | 0.009 | 0.091 | Kinesin-like protein 1 inhibitor | |||
| 0.091 | 0.009 | 0.091 | Kinesin antagonist | |||
| 0.087 | 0.006 | 0.087 | Ryanodine receptor antagonist | 0.075 0.012 DBMET00137 0.074 0.013 DBMET03681 | ||
| 0.092 | 0.011 | 0.092 | Potassium channel intermediate-conductance Ca-activated blocker | 0.075 0.022 DBMET00137 0.071 0.025 DBMET03681 | ||
| 0.201 | 0.121 | 0.537 | 5 Hydroxytryptamine release stimulant | 0.537 0.022 DBMET00137 0.392 0.047 DBMET03681 | DBMET00137 | |
| 0.089 | 0.009 | 0.089 | Histone deacetylase class I inhibitor | |||
| 0.109 | 0.032 | 0.287 | Porphobilinogen synthase inhibitor | 0.287 0.005 DBMET00137 0.184 0.014 DBMET03681 | DBMET00137 | |
| 0.176 | 0.099 | 0.269 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.269 0.034 DBMET00137 0.265 0.036 DBMET03681 | DBMET00137 | |
| 0.157 | 0.082 | 0.157 | Growth hormone agonist | |||
| 0.092 | 0.018 | 0.192 | Acyl-CoA dehydrogenase inhibitor | 0.192 0.006 DBMET00137 0.138 0.01 DBMET03681 | DBMET00137 | |
| 0.079 | 0.006 | 0.079 | Arginase inhibitor | 0.051 0.014 DBMET00137 0.048 0.016 DBMET03681 | ||
| 0.1 | 0.027 | 0.1 | Carbonic anhydrase V inhibitor | 0.07 0.042 DBMET00137 0.069 0.043 DBMET03681 | ||
| 0.185 | 0.113 | 0.57 | Aldehyde oxidase inhibitor | 0.57 0.023 DBMET00137 0.383 0.05 DBMET03681 | DBMET00137 | |
| 0.119 | 0.046 | 0.177 | DOPA decarboxylase inhibitor | 0.177 0.011 DBMET00137 0.146 0.024 DBMET03681 | DBMET00137 | |
| 0.146 | 0.074 | 0.146 | Hemostatic | |||
| 0.084 | 0.015 | 0.084 | Botulinum neurotoxin type A inhibitor | 0.054 0.048 DBMET00137 0.064 0.032 DBMET03681 | ||
| 0.098 | 0.029 | 0.11 | GABA aminotransferase inhibitor | 0.11 0.021 DBMET00137 0.081 0.045 DBMET03681 | DBMET00137 | |
| 0.08 | 0.011 | 0.08 | Dihydroorotate oxidase inhibitor | 0.08 0.01 DBMET00137 0.078 0.011 DBMET03681 | ||
| 0.115 | 0.048 | 0.146 | Carbonic anhydrase III inhibitor | 0.129 0.039 DBMET00137 0.146 0.03 DBMET03681 | DBMET03681 | |
| 0.084 | 0.02 | 0.114 | Glutamate (mGluR6) antagonist | 0.114 0.007 DBMET00137 0.094 0.013 DBMET03681 | DBMET00137 | |
| 0.233 | 0.168 | 0.38 | Calcium channel activator | 0.38 0.033 DBMET00137 0.35 0.05 DBMET03681 | DBMET00137 | |
| 0.085 | 0.021 | 0.085 | Collagenase 3 inhibitor | |||
| 0.111 | 0.048 | 0.214 | Creatine kinase inhibitor | 0.214 0.009 DBMET00137 0.165 0.018 DBMET03681 | DBMET00137 | |
| 0.097 | 0.034 | 0.105 | Na+ K+ transporting ATPase inhibitor | 0.105 0.027 DBMET00137 0.099 0.033 DBMET03681 | DBMET00137 | |
| 0.075 | 0.013 | 0.075 | Carbonic anhydrase IV inhibitor | |||
| 0.091 | 0.029 | 0.091 | Carbonic anhydrase VA inhibitor | 0.076 0.04 DBMET00137 0.069 0.048 DBMET03681 | ||
| 0.125 | 0.063 | 0.125 | Alkylator | 0.108 0.08 DBMET00137 | ||
| 0.131 | 0.071 | 0.155 | Sphingosine 1-phosphate receptor 2 antagonist | 0.155 0.034 DBMET00137 0.126 0.083 DBMET03681 | DBMET00137 | |
| 0.092 | 0.033 | 0.14 | Aminopeptidase I inhibitor | 0.14 0.014 DBMET00137 0.113 0.022 DBMET03681 | DBMET00137 | |
| 0.102 | 0.042 | 0.102 | Phosphodiesterase I inhibitor | |||
| 0.164 | 0.105 | 0.164 | Psychostimulant | 0.149 0.117 DBMET00137 | ||
| 0.097 | 0.039 | 0.097 | Myeloperoxidase inhibitor | 0.085 0.057 DBMET00137 0.082 0.063 DBMET03681 | ||
| 0.136 | 0.078 | 0.215 | Mannose-6-phosphate isomerase inhibitor | 0.215 0.023 DBMET00137 0.17 0.049 DBMET03681 | DBMET00137 | |
| 0.089 | 0.032 | 0.089 | Matrix metalloproteinase inhibitor | |||
| 0.065 | 0.008 | 0.065 | Membrane dipeptidase inhibitor | 0.055 0.012 DBMET00137 0.052 0.014 DBMET03681 | ||
| 0.064 | 0.008 | 0.064 | Vascular adhesion protein 1 inhibitor | 0.037 0.03 DBMET00137 | ||
| 0.077 | 0.022 | 0.077 | Phosphodiesterase 1C inhibitor | 0.058 0.053 DBMET00137 0.06 0.047 DBMET03681 | ||
| 0.077 | 0.022 | 0.156 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.156 0.008 DBMET00137 0.113 0.012 DBMET03681 | DBMET00137 | |
| 0.086 | 0.032 | 0.128 | Glycine receptor agonist | 0.128 0.011 DBMET00137 0.113 0.015 DBMET03681 | DBMET00137 | |
| 0.059 | 0.007 | 0.067 | Kainate receptor agonist | 0.067 0.005 DBMET00137 0.055 0.009 DBMET03681 | DBMET00137 | |
| 0.065 | 0.014 | 0.065 | Thymidylate synthase inhibitor | 0.047 0.031 DBMET00137 | ||
| 0.054 | 0.003 | 0.054 | Purinergic P2Y15 antagonist | 0.047 0.004 DBMET00137 0.047 0.004 DBMET03681 | ||
| 0.143 | 0.096 | 0.219 | Arachidonic acid antagonist | 0.219 0.018 DBMET00137 0.196 0.037 DBMET03681 | DBMET00137 | |
| 0.089 | 0.042 | 0.089 | Somatostatin 1 agonist | |||
| 0.062 | 0.015 | 0.062 | Histone deacetylase 8 inhibitor | |||
| 0.123 | 0.077 | 0.123 | Antibacterial (Helicobacter pylori) | |||
| 0.082 | 0.038 | 0.101 | GABA B receptor agonist | 0.101 0.016 DBMET00137 0.089 0.027 DBMET03681 | DBMET00137 | |
| 0.11 | 0.067 | 0.252 | Cystathionine beta-synthase inhibitor | 0.226 0.019 DBMET00137 0.252 0.015 DBMET03681 | DBMET03681 | |
| 0.069 | 0.026 | 0.069 | Matrix metalloproteinase 1 inhibitor | |||
| 0.059 | 0.017 | 0.059 | Kainate receptor antagonist | |||
| 0.258 | 0.217 | 0.496 | 5 Hydroxytryptamine release inhibitor | 0.496 0.034 DBMET00137 0.394 0.081 DBMET03681 | DBMET00137 | |
| 0.063 | 0.022 | 0.063 | Metalloproteinase-3 inhibitor | |||
| 0.088 | 0.048 | 0.115 | D-Ala-D-Ala ligase inhibitor | 0.115 0.016 DBMET00137 0.099 0.031 DBMET03681 | DBMET00137 | |
| 0.044 | 0.005 | 0.044 | Aggrecanase 2 inhibitor | |||
| 0.052 | 0.013 | 0.072 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.072 0.004 DBMET00137 0.067 0.005 DBMET03681 | DBMET00137 | |
| 0.135 | 0.097 | 0.273 | GABA C receptor rho-2 antagonist | 0.273 0.008 DBMET00137 0.211 0.023 DBMET03681 | DBMET00137 | |
| 0.057 | 0.019 | 0.063 | Dopamine beta hydroxylase inhibitor | 0.063 0.012 DBMET00137 0.061 0.014 DBMET03681 | DBMET00137 | |
| 0.085 | 0.049 | 0.128 | Glycine receptor antagonist | 0.128 0.014 DBMET00137 0.115 0.021 DBMET03681 | DBMET00137 | |
| 0.137 | 0.102 | 0.164 | Melanin inhibitor | 0.164 0.065 DBMET00137 0.149 0.083 DBMET03681 | DBMET00137 | |
| 0.048 | 0.013 | 0.073 | Glutamate (mGluR8) agonist | 0.073 0.005 DBMET00137 0.058 0.008 DBMET03681 | DBMET00137 | |
| 0.052 | 0.02 | 0.07 | Histamine H2 receptor agonist | 0.07 0.01 DBMET00137 0.045 0.027 DBMET03681 | DBMET00137 | |
| 0.047 | 0.015 | 0.094 | Fumarate hydratase inhibitor | 0.094 0.006 DBMET00137 0.06 0.01 DBMET03681 | DBMET00137 | |
| 0.067 | 0.035 | 0.123 | Purinergic P2X1 antagonist | 0.123 0.011 DBMET00137 0.085 0.022 DBMET03681 | DBMET00137 | |
| 0.049 | 0.019 | 0.049 | Histone deacetylase 7 inhibitor | 0.036 0.026 DBMET03681 | ||
| 0.053 | 0.023 | 0.07 | Cytokine production stimulant | 0.056 0.018 DBMET00137 0.07 0.007 DBMET03681 | DBMET03681 | |
| 0.039 | 0.01 | 0.042 | Glutamate (mGluR3) agonist | 0.042 0.008 DBMET00137 0.039 0.011 DBMET03681 | DBMET00137 | |
| 0.047 | 0.018 | 0.047 | Histone deacetylase 9 inhibitor | 0.039 0.027 DBMET03681 | ||
| 0.06 | 0.032 | 0.06 | Matrix metalloproteinase (membrane-type) inhibitor | |||
| 0.091 | 0.065 | 0.163 | Prolactin inhibitor | 0.163 0.017 DBMET00137 0.118 0.039 DBMET03681 | DBMET00137 | |
| 0.034 | 0.009 | 0.034 | Thymidine phosphorylase inhibitor | 0.031 0.011 DBMET00137 0.031 0.011 DBMET03681 | ||
| 0.052 | 0.028 | 0.076 | Adenosine deaminase inhibitor | 0.06 0.021 DBMET00137 0.076 0.01 DBMET03681 | DBMET03681 | |
| 0.066 | 0.042 | 0.081 | Carbonic anhydrase inhibitor | 0.081 0.035 DBMET03681 | DBMET03681 | |
| 0.094 | 0.072 | 0.147 | Anabolic | 0.147 0.019 DBMET00137 0.123 0.036 DBMET03681 | DBMET00137 | |
| 0.089 | 0.067 | 0.158 | HIV-1 integrase (Overall Integration) inhibitor | 0.158 0.023 DBMET00137 0.106 0.049 DBMET03681 | DBMET00137 | |
| 0.085 | 0.063 | 0.141 | Granulocyte macrophage colony stimulating factor agonist | 0.141 0.007 DBMET00137 0.114 0.02 DBMET03681 | DBMET00137 | |
| 0.073 | 0.052 | 0.073 | Phosphodiesterase 4D inhibitor | |||
| 0.025 | 0.003 | 0.025 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.02 0.004 DBMET00137 0.022 0.004 DBMET03681 | ||
| 0.099 | 0.078 | 0.145 | Mucolytic | 0.145 0.036 DBMET00137 0.105 0.071 DBMET03681 | DBMET00137 | |
| 0.163 | 0.144 | 0.173 | Immunostimulant | 0.173 0.137 DBMET00137 0.159 0.148 DBMET03681 | DBMET00137 | |
| 0.107 | 0.087 | 0.107 | MAP kinase kinase inhibitor | |||
| 0.057 | 0.038 | 0.069 | Carbonic anhydrase II inhibitor | 0.069 0.03 DBMET03681 | DBMET03681 | |
| 0.054 | 0.035 | 0.083 | Alpha-mannosidase inhibitor | 0.083 0.01 DBMET00137 0.069 0.017 DBMET03681 | DBMET00137 | |
| 0.036 | 0.018 | 0.036 | Carboxypeptidase B inhibitor | 0.031 0.027 DBMET00137 | ||
| 0.028 | 0.01 | 0.033 | Complement factor 1s inhibitor | 0.033 0.005 DBMET00137 0.028 0.011 DBMET03681 | DBMET00137 | |
| 0.102 | 0.084 | 0.102 | CDK3/cyclin E inhibitor | |||
| 0.098 | 0.08 | 0.098 | Nav1.4 sodium channel blocker | |||
| 0.025 | 0.008 | 0.025 | Aminopeptidase A inhibitor | 0.018 0.013 DBMET03681 | ||
| 0.128 | 0.112 | 0.143 | MAP kinase 3 inhibitor | 0.136 0.092 DBMET00137 0.143 0.08 DBMET03681 | DBMET03681 | |
| 0.041 | 0.026 | 0.078 | Dopamine D5 agonist | 0.078 0.006 DBMET00137 0.067 0.009 DBMET03681 | DBMET00137 | |
| 0.059 | 0.044 | 0.059 | Phosphodiesterase 1B inhibitor | |||
| 0.026 | 0.011 | 0.05 | Glutamate (mGluR1a) agonist | 0.05 0.005 DBMET00137 0.025 0.012 DBMET03681 | DBMET00137 | |
| 0.034 | 0.02 | 0.034 | Dipeptidyl peptidase II inhibitor | 0.03 0.026 DBMET00137 | ||
| 0.036 | 0.023 | 0.036 | Gonadotropin-releasing hormone receptor antagonist | |||
| 0.101 | 0.089 | 0.144 | Microtubule formation inhibitor | 0.144 0.041 DBMET00137 0.115 0.066 DBMET03681 | DBMET00137 | |
| 0.053 | 0.041 | 0.053 | Thromboxane synthase inhibitor | |||
| 0.026 | 0.015 | 0.03 | Glutamate (mGluR1) agonist | 0.03 0.01 DBMET00137 0.024 0.017 DBMET03681 | DBMET00137 | |
| 0.041 | 0.03 | 0.058 | Oxytocin agonist | 0.058 0.019 DBMET00137 0.044 0.028 DBMET03681 | DBMET00137 | |
| 0.047 | 0.038 | 0.049 | Bombesin 2 receptor antagonist | 0.049 0.034 DBMET00137 | DBMET00137 | |
| 0.055 | 0.047 | 0.075 | Carbonic anhydrase stimulant | 0.075 0.029 DBMET00137 0.053 0.049 DBMET03681 | DBMET00137 | |
| 0.14 | 0.132 | 0.235 | Death-associated protein kinase 2 inhibitor | 0.235 0.017 DBMET03681 | DBMET03681 | |
| 0.03 | 0.025 | 0.033 | Methionyl aminopeptidase 1 inhibitor | 0.033 0.021 DBMET00137 | DBMET00137 | |
| 0.017 | 0.012 | 0.037 | Carbonic anhydrase X inhibitor | 0.037 0.004 DBMET00137 0.025 0.005 DBMET03681 | DBMET00137 | |
| 0.017 | 0.012 | 0.037 | Carbonic anhydrase VIII inhibitor | 0.037 0.004 DBMET00137 0.025 0.005 DBMET03681 | DBMET00137 | |
| 0.063 | 0.058 | 0.112 | Glutamate (mGluR7) antagonist | 0.112 0.006 DBMET00137 0.082 0.025 DBMET03681 | DBMET00137 | |
| 0.025 | 0.021 | 0.033 | Lysine carboxypeptidase inhibitor | 0.033 0.013 DBMET00137 0.025 0.021 DBMET03681 | DBMET00137 | |
| 0.064 | 0.06 | 0.113 | Exportin-1 inhibitor | 0.113 0.005 DBMET00137 0.079 0.027 DBMET03681 | DBMET00137 | |
| 0.109 | 0.105 | 0.151 | Protein kinase stimulant | 0.151 0.068 DBMET00137 0.12 0.092 DBMET03681 | DBMET00137 | |
| 0.041 | 0.037 | 0.046 | Fructose-1,6-bisphosphatase inhibitor | 0.046 0.029 DBMET00137 | DBMET00137 | |
| 0.041 | 0.038 | 0.072 | Mannosidase inhibitor | 0.072 0.011 DBMET00137 0.057 0.019 DBMET03681 | DBMET00137 | |
| 0.016 | 0.013 | 0.025 | Telomerase stimulant | 0.025 0.004 DBMET00137 0.021 0.006 DBMET03681 | DBMET00137 | |
| 0.032 | 0.031 | 0.032 | Inosine monophosphate dehydrogenase inhibitor | |||
| 0.074 | 0.073 | 0.088 | Glutathione S-transferase inhibitor | 0.088 0.05 DBMET00137 | DBMET00137 | |
| 0.03 | 0.03 | 0.033 | Kainate receptor 2 antagonist | 0.033 0.028 DBMET00137 | DBMET00137 | |
| 0.01 | 0.011 | 0.019 | Glutamate (mGluR6) agonist | 0.019 0.004 DBMET00137 0.014 0.007 DBMET03681 | DBMET00137 | |
| 0.014 | 0.015 | 0.019 | Purinergic P2Y1 agonist | 0.019 0.007 DBMET00137 0.017 0.009 DBMET03681 | DBMET00137 | |
| 0.102 | 0.103 | 0.168 | Cathepsin H inhibitor | 0.168 0.035 DBMET00137 0.124 0.07 DBMET03681 | DBMET00137 | |
| 0.022 | 0.024 | 0.052 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.052 0.008 DBMET00137 0.039 0.012 DBMET03681 | DBMET00137 | |
| 0.032 | 0.035 | 0.04 | Diamine oxidase inhibitor | 0.04 0.023 DBMET00137 | DBMET00137 | |
| 0.016 | 0.02 | 0.023 | Methylmalonyl-CoA mutase inhibitor | 0.023 0.005 DBMET00137 0.02 0.008 DBMET03681 | DBMET00137 | |
| 0.029 | 0.033 | 0.042 | Phosphoglycerate kinase inhibitor | 0.042 0.018 DBMET00137 0.032 0.029 DBMET03681 | DBMET00137 | |
| 0.101 | 0.106 | 0.124 | Transcription factor STAT6 inhibitor | 0.124 0.054 DBMET00137 0.113 0.074 DBMET03681 | DBMET00137 | |
| 0.031 | 0.037 | 0.048 | Glutamate (mGluR3) antagonist | 0.048 0.014 DBMET00137 0.035 0.027 DBMET03681 | DBMET00137 | |
| 0.054 | 0.06 | 0.079 | 5 Hydroxytryptamine 3 agonist | 0.079 0.028 DBMET00137 0.061 0.046 DBMET03681 | DBMET00137 | |
| 0.02 | 0.025 | 0.026 | Isoleucine-tRNA ligase inhibitor | 0.026 0.01 DBMET00137 0.023 0.014 DBMET03681 | DBMET00137 | |
| 0.022 | 0.029 | 0.037 | Vanilloid 2 agonist | 0.037 0.005 DBMET00137 0.029 0.01 DBMET03681 | DBMET00137 | |
| 0.119 | 0.127 | 0.169 | Sphingosine 1-phosphate receptor 5 antagonist | 0.169 0.034 DBMET00137 0.136 0.087 DBMET03681 | DBMET00137 | |
| 0.007 | 0.015 | 0.01 | Purinergic P2Y2 agonist | 0.01 0.008 DBMET00137 | DBMET00137 | |
| 0.071 | 0.079 | 0.095 | MAP kinase kinase 7 inhibitor | 0.095 0.017 DBMET00137 0.084 0.035 DBMET03681 | DBMET00137 | |
| 0.062 | 0.072 | 0.124 | CYP2A6 inhibitor | 0.124 0.025 DBMET00137 0.091 0.04 DBMET03681 | DBMET00137 | |
| 0.012 | 0.022 | 0.021 | Thromboxane A2 agonist | 0.021 0.005 DBMET00137 0.015 0.011 DBMET03681 | DBMET00137 | |
| 0.02 | 0.03 | 0.049 | Uridine phosphorylase inhibitor | 0.049 0.008 DBMET00137 0.031 0.017 DBMET03681 | DBMET00137 | |
| 0.038 | 0.048 | 0.058 | Histamine H1 receptor agonist | 0.058 0.01 DBMET00137 0.046 0.025 DBMET03681 | DBMET00137 | |
| 0.042 | 0.053 | 0.076 | Carbonic anhydrase VB inhibitor | 0.073 0.026 DBMET00137 0.076 0.024 DBMET03681 | DBMET03681 | |
| 0.004 | 0.018 | 0.009 | DNA topoisomerase III inhibitor | 0.009 0.004 DBMET00137 0.007 0.006 DBMET03681 | DBMET00137 | |
| 0.017 | 0.031 | 0.025 | Neuraminidase (Influenza B) inhibitor | 0.025 0.008 DBMET00137 0.02 0.016 DBMET03681 | DBMET00137 | |
| 0.008 | 0.023 | 0.023 | Lysophosphatidic acid receptor 3 agonist | 0.023 0.005 DBMET00137 0.015 0.008 DBMET03681 | DBMET00137 | |
| 0.073 | 0.09 | 0.108 | mTOR complex 2 inhibitor | 0.108 0.025 DBMET00137 0.084 0.059 DBMET03681 | DBMET00137 | |
| 0.065 | 0.082 | 0.097 | Carbonic anhydrase VI inhibitor | 0.095 0.042 DBMET00137 0.097 0.041 DBMET03681 | DBMET03681 | |
| 0.167 | 0.185 | 0.184 | Transcription factor STAT3 inhibitor | 0.184 0.158 DBMET00137 | DBMET00137 | |
| 0.092 | 0.113 | 0.162 | Aldehyde dehydrogenase inhibitor | 0.162 0.041 DBMET00137 0.131 0.061 DBMET03681 | DBMET00137 | |
| 0.037 | 0.058 | 0.065 | Carbonic anhydrase I inhibitor | 0.065 0.032 DBMET03681 | DBMET03681 | |
| 0.027 | 0.049 | 0.044 | Toll-Like receptor 2 agonist | 0.044 0.027 DBMET00137 | DBMET00137 | |
| 0.007 | 0.029 | 0.018 | Carbonic anhydrase XI inhibitor | 0.018 0.005 DBMET00137 0.012 0.01 DBMET03681 | DBMET00137 | |
| 0.018 | 0.042 | 0.035 | Lysophosphatidic acid receptor 1 agonist | 0.035 0.008 DBMET00137 0.027 0.014 DBMET03681 | DBMET00137 | |
| 0.021 | 0.047 | 0.033 | Calcitonin receptor agonist | 0.033 0.024 DBMET00137 | DBMET00137 | |
| 0.029 | 0.057 | 0.066 | Acid-sensing ion channel blocker | 0.066 0.007 DBMET03681 | DBMET03681 | |
| 0.072 | 0.1 | 0.114 | Estrogen-related receptor beta agonist | 0.114 0.013 DBMET00137 0.097 0.028 DBMET03681 | DBMET00137 | |
| 0.031 | 0.059 | 0.065 | Carbonic anhydrase IX inhibitor | 0.065 0.035 DBMET03681 | DBMET03681 | |
| 0.003 | 0.032 | 0.006 | Integrin alpha5beta6 antagonist | 0.006 0.005 DBMET00137 | DBMET00137 | |
| 0.019 | 0.049 | 0.041 | Potassium channel small-conductance Ca-activated activator | 0.041 0.015 DBMET00137 0.04 0.015 DBMET03681 | DBMET00137 | |
| 0.025 | 0.055 | 0.037 | Melatonin receptor 1A agonist | 0.037 0.018 DBMET00137 | DBMET00137 | |
| 0.164 | 0.195 | 0.21 | Neuropeptide Y2 antagonist | 0.21 0.103 DBMET00137 | DBMET00137 | |
| 0.033 | 0.064 | 0.042 | GABA B receptor antagonist | 0.042 0.032 DBMET00137 | DBMET00137 | |
| 0.029 | 0.06 | 0.039 | AMPA 4 receptor antagonist | 0.039 0.028 DBMET00137 0.037 0.033 DBMET03681 | DBMET00137 | |
| 0.003 | 0.034 | 0.006 | CC chemokine 6 receptor agonist | 0.006 0.004 DBMET00137 | DBMET00137 | |
| 0.015 | 0.047 | 0.024 | Retinoid X beta receptor antagonist | 0.024 0.008 DBMET00137 0.022 0.011 DBMET03681 | DBMET00137 | |
| 0.013 | 0.047 | 0.023 | Antibiotic Anthracycline-like | 0.023 0.007 DBMET00137 0.018 0.015 DBMET03681 | DBMET00137 | |
| 0.115 | 0.148 | 0.186 | Interferon gamma antagonist | 0.186 0.047 DBMET00137 0.156 0.07 DBMET03681 | DBMET00137 | |
| 0.021 | 0.056 | 0.036 | Hedgehog signaling activator | 0.036 0.006 DBMET00137 0.029 0.015 DBMET03681 | DBMET00137 | |
| 0.015 | 0.05 | 0.023 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.023 0.017 DBMET00137 | DBMET00137 | |
| 0.128 | 0.166 | 0.179 | Neurotensin receptor agonist | 0.179 0.05 DBMET00137 0.149 0.104 DBMET03681 | DBMET00137 | |
| 0.004 | 0.042 | 0.01 | Thromboxane agonist | 0.01 0.008 DBMET00137 | DBMET00137 | |
| 0.102 | 0.14 | 0.137 | Vanilloid 1 agonist | 0.137 0.054 DBMET00137 0.113 0.105 DBMET03681 | DBMET00137 | |
| 0.02 | 0.058 | 0.037 | Epoxide hydrolase 1 inhibitor | 0.037 0.014 DBMET00137 | DBMET00137 | |
| 0.029 | 0.067 | 0.061 | Geranyltranstransferase inhibitor | 0.061 0.013 DBMET00137 0.048 0.025 DBMET03681 | DBMET00137 | |
| 0.071 | 0.111 | 0.116 | Expectorant | 0.116 0.054 DBMET00137 | DBMET00137 | |
| 0.024 | 0.064 | 0.039 | Retinoid X alpha receptor antagonist | 0.039 0.017 DBMET00137 0.033 0.025 DBMET03681 | DBMET00137 | |
| 0.085 | 0.125 | 0.155 | Photosensitizer | 0.155 0.028 DBMET00137 0.13 0.046 DBMET03681 | DBMET00137 | |
| 0.04 | 0.08 | 0.054 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.054 0.047 DBMET00137 | DBMET00137 | |
| 0.088 | 0.129 | 0.158 | Toll-Like receptor 2 antagonist | 0.158 0.047 DBMET00137 0.11 0.09 DBMET03681 | DBMET00137 | |
| 0.076 | 0.117 | 0.15 | Carbonic anhydrase XV inhibitor | 0.15 0.031 DBMET00137 0.107 0.058 DBMET03681 | DBMET00137 | |
| 0.057 | 0.097 | 0.122 | Ornithine decarboxylase inhibitor | 0.104 0.04 DBMET00137 0.122 0.024 DBMET03681 | DBMET03681 | |
| 0.048 | 0.089 | 0.082 | Protease 3C (Human rhinovirus) inhibitor | 0.082 0.026 DBMET00137 | DBMET00137 | |
| 0.049 | 0.09 | 0.075 | Interferon inducer | 0.075 0.029 DBMET00137 0.059 0.057 DBMET03681 | DBMET00137 | |
| 0.134 | 0.175 | 0.161 | Histone acetyltransferase inhibitor | 0.161 0.125 DBMET00137 | DBMET00137 | |
| 0.059 | 0.101 | 0.123 | Histamine N-methyltransferase inhibitor | 0.123 0.028 DBMET00137 0.088 0.058 DBMET03681 | DBMET00137 | |
| 0.125 | 0.169 | 0.173 | Insulin sensitizer | 0.173 0.104 DBMET00137 | DBMET00137 | |
| 0.039 | 0.083 | 0.067 | Sphingosine kinase 2 inhibitor | 0.067 0.024 DBMET00137 0.058 0.034 DBMET03681 | DBMET00137 | |
| 0.014 | 0.058 | 0.023 | Factor XIII inhibitor | 0.023 0.01 DBMET00137 | DBMET00137 | |
| 0.009 | 0.053 | 0.022 | Nicotinic acid receptor 1 antagonist | 0.022 0.007 DBMET00137 | DBMET00137 | |
| 0.014 | 0.059 | 0.037 | Nicotinic alpha4beta2 receptor agonist | 0.037 0.01 DBMET00137 0.028 0.02 DBMET03681 | DBMET00137 | |
| 0.027 | 0.072 | 0.037 | Adenosine uptake inhibitor | 0.037 0.017 DBMET00137 | DBMET00137 | |
| 0.053 | 0.098 | 0.108 | Phospholipase D inhibitor | 0.108 0.011 DBMET00137 0.081 0.033 DBMET03681 | DBMET00137 | |
| 0.026 | 0.072 | 0.043 | Retinoid X receptor antagonist | 0.043 0.019 DBMET00137 0.037 0.028 DBMET03681 | DBMET00137 | |
| 0.097 | 0.144 | 0.161 | DNA repair enzyme inhibitor | 0.126 0.061 DBMET00137 0.161 0.023 DBMET03681 | DBMET03681 | |
| 0.017 | 0.064 | 0.028 | Integrin alpha2beta1 antagonist | 0.028 0.015 DBMET00137 | DBMET00137 | |
| 0.04 | 0.087 | 0.063 | Epithelial sodium channel blocker | 0.063 0.025 DBMET00137 | DBMET00137 | |
| 0.024 | 0.073 | 0.037 | Protein kinase (CK2) beta inhibitor | 0.037 0.016 DBMET00137 | DBMET00137 | |
| 0.062 | 0.111 | 0.076 | Histamine H2 receptor antagonist | 0.076 0.074 DBMET00137 | DBMET00137 | |
| 0.035 | 0.085 | 0.077 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.077 0.018 DBMET00137 0.053 0.037 DBMET03681 | DBMET00137 | |
| 0.045 | 0.096 | 0.084 | Carbonic anhydrase XIII inhibitor | 0.084 0.047 DBMET00137 0.077 0.052 DBMET03681 | DBMET00137 | |
| 0.034 | 0.085 | 0.055 | Topoisomerase II beta inhibitor | 0.055 0.027 DBMET00137 | DBMET00137 | |
| 0.008 | 0.059 | 0.018 | Alpha 2a adrenoreceptor agonist | 0.018 0.011 DBMET00137 0.016 0.013 DBMET03681 | DBMET00137 | |
| 0.018 | 0.07 | 0.04 | Retinoid X alpha receptor agonist | 0.04 0.019 DBMET00137 | DBMET00137 | |
| 0.015 | 0.066 | 0.037 | Nicotinic acid receptor 2 antagonist | 0.037 0.006 DBMET00137 0.027 0.017 DBMET03681 | DBMET00137 | |
| 0.027 | 0.079 | 0.05 | Thymidine kinase inhibitor | 0.05 0.019 DBMET00137 0.037 0.036 DBMET03681 | DBMET00137 | |
| 0.025 | 0.078 | 0.041 | Tryptophan 5 hydroxylase inhibitor | 0.041 0.013 DBMET00137 | DBMET00137 | |
| 0.019 | 0.076 | 0.031 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.031 0.01 DBMET00137 0.025 0.023 DBMET03681 | DBMET00137 | |
| 0.022 | 0.079 | 0.032 | Glutamate (mGluR4) agonist | 0.032 0.029 DBMET00137 | DBMET00137 | |
| 0.014 | 0.071 | 0.042 | Nicotinic alpha3beta4 receptor agonist | 0.042 0.009 DBMET00137 0.035 0.015 DBMET03681 | DBMET00137 | |
| 0.024 | 0.081 | 0.068 | Guanylate cyclase inhibitor | 0.068 0.005 DBMET00137 0.053 0.018 DBMET03681 | DBMET00137 | |
| 0.071 | 0.131 | 0.137 | Glutamate release inhibitor | 0.137 0.014 DBMET00137 0.101 0.041 DBMET03681 | DBMET00137 | |
| 0.026 | 0.086 | 0.049 | Dihydroorotase inhibitor | 0.049 0.026 DBMET00137 | DBMET00137 | |
| 0.067 | 0.128 | 0.131 | Lanosterol 14 alpha demethylase inhibitor | 0.131 0.021 DBMET00137 0.118 0.033 DBMET03681 | DBMET00137 | |
| 0.127 | 0.188 | 0.288 | Interleukin agonist | 0.288 0.054 DBMET00137 0.236 0.09 DBMET03681 | DBMET00137 | |
| 0.012 | 0.073 | 0.027 | Prostaglandin F2 alpha agonist | 0.027 0.011 DBMET00137 | DBMET00137 | |
| 0.165 | 0.227 | 0.215 | Antithrombotic | 0.215 0.159 DBMET00137 | DBMET00137 | |
| 0.037 | 0.099 | 0.064 | Cyclin D1 inhibitor | 0.064 0.036 DBMET00137 | DBMET00137 | |
| 0.013 | 0.076 | 0.038 | Retinoid X receptor agonist | 0.038 0.024 DBMET00137 | DBMET00137 | |
| 0.053 | 0.116 | 0.09 | Interferon agonist | 0.09 0.038 DBMET00137 | DBMET00137 | |
| 0.027 | 0.091 | 0.054 | AICAR transformylase inhibitor | 0.054 0.018 DBMET00137 0.041 0.036 DBMET03681 | DBMET00137 | |
| 0.022 | 0.087 | 0.038 | Integrin alpha2 antagonist | 0.038 0.023 DBMET00137 | DBMET00137 | |
| 0.008 | 0.074 | 0.018 | Complement factor D inhibitor | 0.018 0.012 DBMET00137 | DBMET00137 | |
| 0.109 | 0.176 | 0.188 | CF transmembrane conductance regulator agonist | 0.188 0.029 DBMET00137 0.149 0.078 DBMET03681 | DBMET00137 | |
| 0.01 | 0.077 | 0.018 | Alpha 2b adrenoreceptor agonist | 0.018 0.016 DBMET00137 | DBMET00137 | |
| 0.012 | 0.08 | 0.025 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.025 0.007 DBMET00137 | DBMET00137 | |
| 0.018 | 0.086 | 0.034 | Estrogen-related receptor gamma antagonist | 0.034 0.009 DBMET00137 0.029 0.018 DBMET03681 | DBMET00137 | |
| 0.041 | 0.111 | 0.078 | Pregnane X receptor antagonist | 0.078 0.007 DBMET00137 0.062 0.027 DBMET03681 | DBMET00137 | |
| 0.03 | 0.1 | 0.056 | Aldosterone antagonist | 0.056 0.023 DBMET00137 | DBMET00137 | |
| 0.028 | 0.099 | 0.077 | Lysophosphatidic acid 3 receptor antagonist | 0.069 0.015 DBMET00137 0.077 0.01 DBMET03681 | DBMET03681 | |
| 0.006 | 0.079 | 0.02 | Cyclin T1 inhibitor | 0.02 0.011 DBMET00137 | DBMET00137 | |
| 0.018 | 0.091 | 0.049 | Dihydropteroate synthase inhibitor | 0.049 0.018 DBMET00137 | DBMET00137 | |
| 0.018 | 0.092 | 0.07 | Alpha 1d adrenoreceptor agonist | 0.07 0.007 DBMET00137 0.049 0.017 DBMET03681 | DBMET00137 | |
| 0.016 | 0.09 | 0.056 | Carbonic anhydrase XII inhibitor | 0.056 0.035 DBMET03681 | DBMET03681 | |
| 0.025 | 0.099 | 0.06 | Nerve growth factor antagonist | 0.06 0.01 DBMET00137 0.041 0.032 DBMET03681 | DBMET00137 | |
| 0.015 | 0.09 | 0.031 | Acid ceramidase inhibitor | 0.031 0.008 DBMET00137 | DBMET00137 | |
| 0.02 | 0.097 | 0.057 | GABA uptake inhibitor | 0.057 0.011 DBMET00137 0.037 0.031 DBMET03681 | DBMET00137 | |
| 0.047 | 0.127 | 0.075 | Transcription factor RelA inhibitor | 0.075 0.022 DBMET00137 0.063 0.047 DBMET03681 | DBMET00137 | |
| 0.015 | 0.095 | 0.031 | MAP3K8 inhibitor | 0.031 0.017 DBMET00137 | DBMET00137 | |
| 0.024 | 0.104 | 0.046 | Potassium channel Kv1.1 blocker | 0.046 0.016 DBMET00137 | DBMET00137 | |
| 0.03 | 0.113 | 0.049 | HCV NS3/NS4A protease inhibitor | 0.049 0.033 DBMET00137 0.046 0.04 DBMET03681 | DBMET00137 | |
| 0.042 | 0.125 | 0.058 | Leukotriene C antagonist | 0.058 0.035 DBMET00137 | DBMET00137 | |
| 0.071 | 0.154 | 0.131 | Glutamate (mGluR7) agonist | 0.131 0.021 DBMET00137 0.099 0.063 DBMET03681 | DBMET00137 | |
| 0.01 | 0.094 | 0.025 | Protease (Human cytomegalovirus) inhibitor | 0.025 0.011 DBMET00137 | DBMET00137 | |
| 0.054 | 0.138 | 0.109 | Vanilloid 4 agonist | 0.109 0.011 DBMET00137 0.087 0.03 DBMET03681 | DBMET00137 | |
| 0.009 | 0.095 | 0.017 | Estrogen-related receptor gamma agonist | 0.017 0.016 DBMET00137 | DBMET00137 | |
| 0.123 | 0.21 | 0.202 | Cyclic AMP phosphodiesterase inhibitor | 0.202 0.092 DBMET00137 | DBMET00137 | |
| 0.024 | 0.113 | 0.041 | Glutamate (mGluR group III) agonist | 0.041 0.033 DBMET00137 | DBMET00137 | |
| 0.027 | 0.116 | 0.037 | Leukotriene C4 antagonist | 0.037 0.032 DBMET00137 | DBMET00137 | |
| 0.096 | 0.187 | 0.126 | Neuropeptide Y1 antagonist | 0.126 0.108 DBMET00137 | DBMET00137 | |
| 0.063 | 0.154 | 0.084 | Xanthine oxidase inhibitor | 0.084 0.083 DBMET00137 | DBMET00137 | |
| 0.046 | 0.141 | 0.059 | Beta 2 adrenoreceptor agonist | 0.059 0.054 DBMET00137 | DBMET00137 | |
| 0.051 | 0.147 | 0.076 | MDM2 inhibitor | 0.076 0.026 DBMET00137 | DBMET00137 | |
| 0.142 | 0.237 | 0.333 | Cholesterol antagonist | 0.333 0.072 DBMET00137 0.226 0.143 DBMET03681 | DBMET00137 | |
| 0.107 | 0.205 | 0.163 | Lipocortins synthesis antagonist | 0.163 0.088 DBMET03681 | DBMET03681 | |
| 0.051 | 0.15 | 0.108 | Alcohol dehydrogenase inhibitor | 0.108 0.044 DBMET00137 | DBMET00137 | |
| 0.006 | 0.105 | 0.016 | Nicotinic alpha4 receptor agonist | 0.016 0.011 DBMET00137 | DBMET00137 | |
| 0.049 | 0.152 | 0.074 | Inducible nitric-oxide synthase inhibitor | 0.074 0.073 DBMET00137 | DBMET00137 | |
| 0.007 | 0.109 | 0.014 | Cyclin D2 inhibitor | 0.014 0.007 DBMET00137 | DBMET00137 | |
| 0.041 | 0.145 | 0.06 | Beta 3 adrenoreceptor antagonist | 0.06 0.056 DBMET00137 | DBMET00137 | |
| 0.03 | 0.136 | 0.055 | Heparanase inhibitor | 0.055 0.033 DBMET00137 | DBMET00137 | |
| 0.07 | 0.177 | 0.131 | TRPA1 agonist | 0.131 0.047 DBMET00137 0.101 0.085 DBMET03681 | DBMET00137 | |
| 0.043 | 0.15 | 0.065 | Histone deacetylase SIRT3 inhibitor | 0.065 0.037 DBMET00137 | DBMET00137 | |
| 0.158 | 0.268 | 0.411 | Histamine release inhibitor | 0.411 0.07 DBMET00137 0.258 0.149 DBMET03681 | DBMET00137 | |
| 0.021 | 0.131 | 0.039 | Sphingosine kinase 1 inhibitor | 0.039 0.032 DBMET00137 | DBMET00137 | |
| 0.027 | 0.14 | 0.058 | Potassium channel (ATP-sensitive) activator | 0.058 0.018 DBMET00137 | DBMET00137 | |
| 0.013 | 0.127 | 0.027 | 5 Hydroxytryptamine 6 agonist | 0.027 0.023 DBMET00137 | DBMET00137 | |
| 0.029 | 0.143 | 0.061 | Potassium channel (Inward rectifier) activator | 0.061 0.019 DBMET00137 | DBMET00137 | |
| 0.106 | 0.222 | 0.233 | Neurotrophic factor enhancer | 0.233 0.049 DBMET00137 0.175 0.103 DBMET03681 | DBMET00137 | |
| 0.018 | 0.134 | 0.041 | Delayed rectifier potassium channel blocker | 0.041 0.019 DBMET00137 | DBMET00137 | |
| 0.086 | 0.203 | 0.125 | Cyclin-dependent kinase 8 inhibitor | 0.125 0.11 DBMET00137 | DBMET00137 | |
| 0.032 | 0.15 | 0.06 | Sphingosine kinase inhibitor | 0.06 0.038 DBMET00137 | DBMET00137 | |
| 0.115 | 0.233 | 0.157 | Heat shock protein 70 antagonist | 0.157 0.033 DBMET00137 0.135 0.098 DBMET03681 | DBMET00137 | |
| 0.058 | 0.178 | 0.1 | Proteasome inhibitor | 0.1 0.088 DBMET00137 | DBMET00137 | |
| 0.082 | 0.203 | 0.138 | Pyruvate kinase inhibitor | 0.138 0.126 DBMET00137 | DBMET00137 | |
| 0.021 | 0.144 | 0.038 | 5 Hydroxytryptamine 2B agonist | 0.038 0.028 DBMET00137 | DBMET00137 | |
| 0.03 | 0.157 | 0.05 | Heme oxygenase inhibitor | 0.05 0.013 DBMET00137 | DBMET00137 | |
| 0.013 | 0.14 | 0.033 | ATP citrate lysase inhibitor | 0.033 0.021 DBMET00137 | DBMET00137 | |
| 0.033 | 0.162 | 0.072 | Cathepsin G inhibitor | 0.072 0.051 DBMET00137 | DBMET00137 | |
| 0.008 | 0.139 | 0.025 | Sodium/glucose cotransporter 2 inhibitor | 0.025 0.021 DBMET00137 | DBMET00137 | |
| 0.007 | 0.139 | 0.022 | Imidazoline I1 receptor antagonist | 0.022 0.013 DBMET00137 | DBMET00137 | |
| 0.007 | 0.14 | 0.016 | CC chemokine 9 receptor antagonist | 0.016 0.015 DBMET00137 | DBMET00137 | |
| 0.035 | 0.168 | 0.076 | Corticotropin releasing factor 2 receptor antagonist | 0.076 0.021 DBMET00137 | DBMET00137 | |
| 0.091 | 0.225 | 0.175 | I kappa B kinase epsilon inhibitor | 0.175 0.094 DBMET00137 | DBMET00137 | |
| 0.108 | 0.243 | 0.188 | Calpain inhibitor | 0.188 0.125 DBMET00137 | DBMET00137 | |
| 0.053 | 0.189 | 0.102 | Bromodomain-containing protein 2 inhibitor | 0.102 0.038 DBMET00137 | DBMET00137 | |
| 0.027 | 0.164 | 0.063 | Squalene epoxidase inhibitor | 0.063 0.018 DBMET00137 | DBMET00137 | |
| 0.014 | 0.153 | 0.04 | Angiotensin AT1 receptor antagonist | 0.04 0.033 DBMET00137 | DBMET00137 | |
| 0.006 | 0.146 | 0.03 | Acetylcholine M4 receptor agonist | 0.03 0.022 DBMET00137 | DBMET00137 | |
| 0.01 | 0.151 | 0.024 | Sodium/glucose cotransporter inhibitor | 0.024 0.023 DBMET00137 | DBMET00137 | |
| 0.03 | 0.172 | 0.047 | CD45 antagonist | 0.047 0.042 DBMET00137 | DBMET00137 | |
| 0.017 | 0.162 | 0.037 | MAP3K5 inhibitor | 0.037 0.03 DBMET00137 | DBMET00137 | |
| 0.02 | 0.167 | 0.106 | Acetylcholine M5 receptor agonist | 0.106 0.017 DBMET00137 | DBMET00137 | |
| 0.024 | 0.172 | 0.058 | Sphingosine 1-phosphate receptor 3 antagonist | 0.058 0.042 DBMET00137 | DBMET00137 | |
| 0.025 | 0.173 | 0.088 | Sphingosine 1-phosphate receptor 4 agonist | 0.088 0.031 DBMET00137 | DBMET00137 | |
| 0.01 | 0.16 | 0.032 | Nicotinic acid receptor agonist | 0.032 0.031 DBMET00137 | DBMET00137 | |
| 0.015 | 0.167 | 0.038 | Ceramide glucosyltransferase inhibitor | 0.038 0.021 DBMET00137 | DBMET00137 | |
| 0.061 | 0.215 | 0.157 | Cyclooxygenase 3 inhibitor | 0.157 0.042 DBMET00137 0.107 0.093 DBMET03681 | DBMET00137 | |
| 0.117 | 0.272 | 0.188 | Transcription factor NF kappa B inhibitor | 0.188 0.181 DBMET00137 | DBMET00137 | |
| 0.094 | 0.251 | 0.15 | Focal adhesion kinase 2 inhibitor | 0.15 0.131 DBMET00137 | DBMET00137 | |
| 0.058 | 0.216 | 0.102 | CC chemokine 5 receptor agonist | 0.102 0.019 DBMET00137 0.084 0.051 DBMET03681 | DBMET00137 | |
| 0.051 | 0.21 | 0.099 | Beta glucuronidase inhibitor | 0.099 0.071 DBMET00137 | DBMET00137 | |
| 0.072 | 0.233 | 0.138 | Sphingosine 1-phosphate receptor 4 antagonist | 0.138 0.045 DBMET00137 | DBMET00137 | |
| 0.023 | 0.185 | 0.067 | Androgen agonist | 0.067 0.034 DBMET00137 | DBMET00137 | |
| 0.015 | 0.177 | 0.031 | Glucosylceramidase stimulant | 0.031 0.011 DBMET00137 | DBMET00137 | |
| 0.039 | 0.203 | 0.148 | Falcipain 3 inhibitor | 0.148 0.038 DBMET00137 0.087 0.085 DBMET03681 | DBMET00137 | |
| 0.03 | 0.194 | 0.056 | Glucosylceramidase inhibitor | 0.056 0.036 DBMET00137 | DBMET00137 | |
| 0.025 | 0.194 | 0.041 | CF transmembrane conductance regulator antagonist | 0.041 0.024 DBMET00137 | DBMET00137 | |
| 0.065 | 0.236 | 0.107 | Interleukin 8 antagonist | 0.107 0.081 DBMET00137 | DBMET00137 | |
| 0.011 | 0.185 | 0.042 | Glutamate (mGluR group I) agonist | 0.042 0.04 DBMET00137 | DBMET00137 | |
| 0.043 | 0.221 | 0.073 | Calcium channel P-type blocker | 0.073 0.022 DBMET00137 | DBMET00137 | |
| 0.027 | 0.208 | 0.089 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.089 0.044 DBMET00137 | DBMET00137 | |
| 0.015 | 0.197 | 0.053 | Glutamate (mGluR1a) antagonist | 0.041 0.028 DBMET00137 0.053 0.019 DBMET03681 | DBMET03681 | |
| 0.084 | 0.272 | 0.219 | 3C-like protease (Human coronavirus) inhibitor | 0.219 0.042 DBMET00137 | DBMET00137 | |
| 0.021 | 0.209 | 0.047 | Purinergic P2X4 antagonist | 0.047 0.03 DBMET00137 | DBMET00137 | |
| 0.01 | 0.2 | 0.032 | Lysophosphatidic acid 2 receptor antagonist | 0.032 0.019 DBMET00137 | DBMET00137 | |
| 0.046 | 0.238 | 0.188 | Amylase inhibitor | 0.188 0.048 DBMET00137 0.101 0.095 DBMET03681 | DBMET00137 | |
| 0.019 | 0.217 | 0.048 | CC chemokine 4 receptor antagonist | 0.048 0.031 DBMET00137 | DBMET00137 | |
| 0.029 | 0.23 | 0.059 | Phosphodiesterase 1A inhibitor | 0.059 0.044 DBMET00137 | DBMET00137 | |
| 0.067 | 0.269 | 0.13 | Thiol protease inhibitor | 0.13 0.097 DBMET00137 | DBMET00137 | |
| 0.056 | 0.263 | 0.139 | Acetylcholine release stimulant | 0.139 0.024 DBMET00137 | DBMET00137 | |
| 0.09 | 0.299 | 0.257 | 5 Hydroxytryptamine 1E antagonist | 0.257 0.067 DBMET00137 0.178 0.157 DBMET03681 | DBMET00137 | |
| 0.052 | 0.263 | 0.099 | Phosphodiesterase 6D inhibitor | 0.099 0.055 DBMET00137 | DBMET00137 | |
| 0.111 | 0.323 | 0.27 | Vasodilator, peripheral | 0.27 0.113 DBMET00137 0.192 0.186 DBMET03681 | DBMET00137 | |
| 0.019 | 0.235 | 0.046 | Vanilloid 3 antagonist | 0.046 0.012 DBMET00137 | DBMET00137 | |
| 0.036 | 0.252 | 0.14 | Cholesterol synthesis inhibitor | 0.14 0.05 DBMET00137 0.095 0.094 DBMET03681 | DBMET00137 | |
| 0.041 | 0.261 | 0.098 | Bile acid receptor antagonist | 0.098 0.053 DBMET00137 | DBMET00137 | |
| 0.006 | 0.227 | 0.036 | Free fatty acid receptor 1 antagonist | 0.036 0.02 DBMET00137 | DBMET00137 | |
| 0.015 | 0.237 | 0.061 | Cyclin-dependent kinase 6 inhibitor | 0.061 0.04 DBMET00137 | DBMET00137 | |
| 0.019 | 0.241 | 0.071 | Protein kinase C beta inhibitor | 0.071 0.046 DBMET00137 | DBMET00137 | |
| 0.01 | 0.234 | 0.044 | Glutamate (mGluR5) agonist | 0.044 0.034 DBMET00137 | DBMET00137 | |
| 0.023 | 0.248 | 0.054 | 5 Hydroxytryptamine 7 agonist | 0.054 0.043 DBMET00137 | DBMET00137 | |
| 0.045 | 0.272 | 0.132 | Cytidine deaminase inhibitor | 0.132 0.089 DBMET00137 | DBMET00137 | |
| 0.014 | 0.243 | 0.053 | Prolyl endopeptidase inhibitor | 0.053 0.032 DBMET00137 | DBMET00137 | |
| 0.039 | 0.268 | 0.102 | Protein kinase C gamma inhibitor | 0.102 0.074 DBMET00137 | DBMET00137 | |
| 0.049 | 0.281 | 0.161 | Aryl hydrocarbon receptor agonist | 0.161 0.127 DBMET00137 | DBMET00137 | |
| 0.024 | 0.257 | 0.063 | Nicotinic alpha3beta2 receptor antagonist | 0.063 0.023 DBMET00137 | DBMET00137 | |
| 0.036 | 0.271 | 0.082 | Protein kinase C zeta inhibitor | 0.082 0.081 DBMET00137 | DBMET00137 | |
| 0.107 | 0.349 | 0.278 | Vasodilator, coronary | 0.278 0.107 DBMET00137 0.197 0.185 DBMET03681 | DBMET00137 | |
| 0.027 | 0.27 | 0.065 | Secretase beta inhibitor | 0.065 0.058 DBMET00137 | DBMET00137 | |
| 0.052 | 0.296 | 0.281 | Acetylcholine M1 receptor antagonist | 0.281 0.018 DBMET03681 | DBMET03681 | |
| 0.014 | 0.268 | 0.045 | Benzodiazepine antagonist | 0.045 0.039 DBMET00137 | DBMET00137 | |
| 0.009 | 0.276 | 0.041 | Potassium channel Kv1.3 blocker | 0.041 0.04 DBMET00137 | DBMET00137 | |
| 0.015 | 0.282 | 0.046 | Cholesterol esterase inhibitor | 0.046 0.036 DBMET00137 | DBMET00137 | |
| 0.025 | 0.303 | 0.084 | Potassium channel (Tandem pore domain) blocker | 0.084 0.026 DBMET00137 | DBMET00137 | |
| 0.056 | 0.337 | 0.162 | Hexokinase inhibitor | 0.162 0.066 DBMET00137 | DBMET00137 | |
| 0.024 | 0.307 | 0.07 | Macrophage migration inhibitory factor inhibitor | 0.07 0.066 DBMET00137 | DBMET00137 | |
| 0.02 | 0.305 | 0.101 | Calcium antagonist | 0.101 0.047 DBMET00137 | DBMET00137 | |
| 0.014 | 0.305 | 0.089 | Nicotinic alpha4beta2 receptor antagonist | 0.089 0.041 DBMET00137 | DBMET00137 | |
| 0.022 | 0.314 | 0.065 | Aryl hydrocarbon receptor antagonist | 0.065 0.044 DBMET00137 | DBMET00137 | |
| 0.015 | 0.344 | 0.094 | Anesthetic local | 0.094 0.088 DBMET00137 | DBMET00137 | |
| 0.028 | 0.361 | 0.184 | Acetylcholine muscarinic antagonist | 0.184 0.029 DBMET03681 | DBMET03681 | |
| 0.056 | 0.396 | 0.152 | Pregnane X receptor agonist | 0.152 0.05 DBMET00137 | DBMET00137 | |
| 0.027 | 0.402 | 0.194 | Cholinergic antagonist | 0.194 0.034 DBMET03681 | DBMET03681 | |
| 0.027 | 0.411 | 0.142 | Nav1.6 sodium channel blocker | 0.142 0.063 DBMET00137 | DBMET00137 | |
| 0.024 | 0.431 | 0.172 | Acetylcholine antagonist | 0.172 0.039 DBMET03681 | DBMET03681 | |
| 0.022 | 0.439 | 0.089 | Interleukin 1 beta converting enzyme inhibitor | 0.089 0.073 DBMET00137 | DBMET00137 | |
| 0.048 | 0.466 | 0.21 | Calpain 2 inhibitor | 0.21 0.179 DBMET00137 | DBMET00137 | |
| 0.031 | 0.456 | 0.161 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.161 0.13 DBMET00137 | DBMET00137 | |
| 0.018 | 0.45 | 0.087 | Caspase 7 inhibitor | 0.087 0.047 DBMET00137 | DBMET00137 | |
| 0.021 | 0.458 | 0.103 | Caspase 3 inhibitor | 0.103 0.086 DBMET00137 | DBMET00137 | |
| 0.014 | 0.479 | 0.067 | Orexin receptor 1 antagonist | 0.067 0.066 DBMET00137 | DBMET00137 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |